Zacks Investment Research · Nov 8, 2023
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
NASDAQ · AVRO
AVROBIO, Inc.
Healthcare · Biotechnology
$1.40
Down-$0.02 (-1.41%)
Updated Aug 25, 2026, 6:57 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.24M
- P/E ratio
- -5.41
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 204.38K
- Avg. volume
- 19.26K
Price performance
AVRO price history
1M range · 0 trading sessions · Daily adjusted prices
AVRO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest AVRO news
The latest Smart Investors Daily articles mentioning AVRO.
Stock researchCompany · Overview
AVRO research
Overview
Company profile and research snapshot.
Company profile
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 18, 2023 | Mizuho | Neutral | — |
| Jul 13, 2023 | Wells Fargo | Overweight | — |
| Jul 12, 2023 | Wedbush | Neutral | — |
| Mar 24, 2023 | Mizuho | Buy | — |
| Mar 24, 2023 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Oct 23, 2023
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Zacks Investment Research · Oct 6, 2023
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
PennyStocks · Jul 13, 2023
Getting Started Trading Penny Stocks? Top Tips
Use these tips to start trading penny stocks The post Getting Started Trading Penny Stocks? Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
